Citation Report
List of articles citing

# Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial

DOI: 10.1136/annrheumdis-2016-210236
Annals of the Rheumatic Diseases, 2017, 76, 1219-1227.

**Source:** https://exaly.com/paper-pdf/66044731/citation-report.pdf
**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|---|---|---|---|
| 120 | Ambrisentan: a review of its use in pulmonary arterial hypertension. **2017**, 11, 233-244 | | 12 |
| 119 | Pulmonary arterial hypertension: screening challenges in systemic sclerosis and future directions. **2017**, 49, | | 3 |
| 118 | Epidemiology and treatment of pulmonary arterial hypertension. **2017**, 14, 603-614 | | 182 |
| 117 | Pulmonary hypertension in systemic sclerosis: different phenotypes. **2017**, 26, | | 59 |
| 116 | New insights into the recognition, classification and management of systemic sclerosis-associated pulmonary hypertension. **2017**, 29, 561-567 | | 3 |
| 115 | Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. **2017**, 50, | | 58 |
| 114 | Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. **2017**, 9, 731-739 | | 13 |
| 113 | Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives. **2018**, 38, 949-958 | | 15 |
| 112 | An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. **2018**, 20, 10 | | 15 |
| 111 | [Pulmonary hypertension in connective tissue disease]. **2018**, 77, 219-230 | | |
| 110 | Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study. **2018**, 17, 612-618 | | 3 |
| 109 | Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects. **2018**, 48, e12876 | | 17 |
| 108 | Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study). **2018**, 19, 12-17 | | 15 |
| 107 | Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. **2018**, 82, 546-554 | | 23 |
| 106 | Pulmonary hypertension in patients with interstitial lung disease. **2018**, 50, 38-46 | | 13 |
| 105 | Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. **2018**, 197, 388-391 | | 24 |
| 104 | Prevalence of pulmonary hypertension in patients with systemic sclerosis and mixed connective tissue disease. **2018**, 97, e11437 | | 8 |

| | | |
|---|---|---|
| 103 | Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model. **2018**, 52, | 17 |
| 102 | Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?. **2018**, 14, 253-264 | 20 |
| 101 | Treatment Algorithms for Systemic Sclerosis According to Experts. **2018**, 70, 1820-1828 | 120 |
| 100 | Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). **2018**, 154, 862-871 | 47 |
| 99 | Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?. **2018**, 264, 187 | |
| 98 | Ambrisentan ́ tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU. **2018**, 34, 289-299 | |
| 97 | Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension.. **2018**, 3, 30-38 | 2 |
| 96 | Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment. **2018**, 2018, 6930297 | 22 |
| 95 | Pulmonary Circulation on the Crossroads Between the Left and Right Heart in Systemic Sclerosis: A Clinical Challenge for Cardiologists and Rheumatologists. **2018**, 14, 271-281 | 8 |
| 94 | [What rheumatologists can learn from pneumologists]. **2018**, 77, 477-483 | 1 |
| 93 | Hypertension pulmonaire et connectivites. **2018**, 85, 210-220 | |
| 92 | Major lung complications of systemic sclerosis. **2018**, 14, 511-527 | 43 |
| 91 | Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease. **2019**, 40, 501-518 | 13 |
| 90 | Screening for pulmonary arterial hypertension in systemic sclerosis. **2019**, 28, | 21 |
| 89 | A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. **2019**, 21, 202 | 10 |
| 88 | Advances in Management of Pulmonary Hypertension Associated with Systemic Sclerosis. **2019**, | 1 |
| 87 | Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. **2019**, 244, 120-131 | 16 |
| 86 | Pulmonary Hypertension Associated with Connective Tissue Disease. **2019**, 40, 173-183 | 15 |

| | | |
|---|---|---|
| 85 | Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. **2019**, 71, 1691-1700 | 7 |
| 84 | Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). **2019**, 83, 842-945 | 67 |
| 83 | OP0067 UTILITY OF RISK STRATIFICATION IN PREDICTING OUTCOMES OF INITIAL MONOTHERAPY VERSUS COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE: A POST-HOC ANALYSIS OF THE AMBITION STUDY. **2019**, | |
| 82 | OP0068 ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS□RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL. **2019**, | 1 |
| 81 | Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH). **2019**, 15, 1427-1442 | 6 |
| 80 | Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment. **2019**, 11, 323-333 | 8 |
| 79 | Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. **2019**, 94, 309-325 | 37 |
| 78 | Pulmonary arterial hypertension: In Asia, as elsewhere, still a lethal disease despite modern treatment. **2019**, 24, 99-100 | 1 |
| 77 | Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. **2019**, 46, 176-183 | 14 |
| 76 | Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. **2020**, 47, 89-98 | 7 |
| 75 | Systemic sclerosis: Recent insight in clinical management. **2020**, 87, 293-299 | 18 |
| 74 | Combination therapy with bosentan and sildenafil for refractory digital ulcers and Raynaud's phenomenon in a 30-year-old woman with systemic sclerosis: Case report and literature review.. **2020**, 5, 159-164 | |
| 73 | Survival Improved in Patients Aged ⩾70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. **2020**, 157, 945-954 | 5 |
| 72 | Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort. **2020**, 50, 473-479 | 8 |
| 71 | Patient-reported outcome instruments in clinical trials of systemic sclerosis.. **2020**, 5, 90-102 | 8 |
| 70 | Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. **2020**, 39, 1389-1397 | 3 |
| 69 | Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis. **2020**, 23, 1276-1287 | 1 |
| 68 | Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis. **2020**, 20, 339 | 0 |

| | | | |
|---|---|---|---|
| 67 | Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. **2020**, 16, 993-1004 | | 4 |
| 66 | Effect of ambrisentan on echocardiographic and Doppler measures from patients in China with pulmonary arterial hypertension. **2020**, 18, 643-649 | | 0 |
| 65 | Pharmacological treatment of systemic sclerosis-associated pulmonary hypertension: A systematic literature review. **2020**, 27, 135-145 | | |
| 64 | Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. **2020**, 78, 17-25 | | 13 |
| 63 | Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. **2020**, 2, e173-e184 | | 8 |
| 62 | Management of systemic sclerosis: the first five years. **2020**, 32, 228-237 | | 15 |
| 61 | Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. **2020**, 21, | | 8 |
| 60 | A case report, a case who developed limited cutaneous scleroderma and pulmonary hypertension 8 years after diagnosis of anti-centromere antibody-positive Sj□gren syndrome. **2020**, 4, 248-252 | | 1 |
| 59 | The future of treatment in systemic sclerosis: can we design better trials?. **2020**, 2, e185-e194 | | 8 |
| 58 | Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease. **2020**, 8, 226-227 | | 0 |
| 57 | The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. **2020**, 2020, 1631735 | | 5 |
| 56 | Systemic sclerosis: Advances towards stratified medicine. **2020**, 34, 101469 | | 3 |
| 55 | Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. **2020**, 13, 15-29 | | 13 |
| 54 | Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. *Annals of the Rheumatic Diseases*, **2020**, 79, 626-634 | 2.4 | 11 |
| 53 | Donn□s r□centes sur la prise en charge clinique de la scl□odermie syst□mique. **2021**, 88, 24-31 | | |
| 52 | Pulmonary hypertension in connective tissue diseases, new evidence and challenges. **2021**, 51, e13453 | | 9 |
| 51 | Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. **2021**, 73, 295-304 | | 10 |
| 50 | Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. **2021**, 203, 484-492 | | 12 |

| | | | |
|---|---|---|---|
| 49 | The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis. **2021**, 31, 151-161 | | 2 |
| 48 | Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review. **2021**, 1 | | 9 |
| 47 | The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. **2021**, 3, e149-e159 | | 4 |
| 46 | Performance Under Pressure: The Relevance of Pulmonary Vascular Response to Exercise Challenge in Scleroderma. **2021**, 159, 481-483 | | 1 |
| 45 | Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. **2021**, 15, 493-504 | | 2 |
| 44 | Group 3 Pulmonary Hypertension: A Review of Diagnostics and Clinical Trials. **2021**, 42, 59-70 | | 3 |
| 43 | Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. **2021**, 14, | | 2 |
| 42 | Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. **2021**, 73, 837-847 | | 9 |
| 41 | Combining Data Sets as Well as Therapies Shows Improved Outcome in Connective Tissue Disease-Associated Pulmonary Hypertension. **2021**, 73, 725-727 | | 1 |
| 40 | Pulmonary arterial hypertension in systemic sclerosis. **2021**, 50, 104062 | | 2 |
| 39 | Clinical characteristics and survival of patients with three major connective tissue diseases associated with pulmonary hypertension: A study from China. **2021**, 22, 925 | | 2 |
| 38 | An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. **2021**, 23, 155 | | 8 |
| 37 | Recognition and Management of Cutaneous Connective Tissue Diseases. **2021**, 105, 757-782 | | 0 |
| 36 | The Role of Exercise Doppler Echocardiography to Unmask Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis and Equivocal Baseline Echocardiographic Values for Pulmonary Hypertension. **2021**, 11, | | 3 |
| 35 | [Characteristics of patients with connective tissue disease-associated pulmonary arterial hypertension treated with prostanoids: A multicenter retrospective study]. **2021**, 42, 825-831 | | |
| 34 | Systemic sclerosis-associated pulmonary arterial hypertension in children. **2021**, 11, 1137-1143 | | 0 |
| 33 | Pulmonary hypertension phenotypes in patients with systemic sclerosis. **2021**, 30, | | 5 |
| 32 | Low-Dose Dobutamine Stress Echocardiography for the Early Detection of Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis Whose Resting Echocardiography Is Non-Diagnostic for Pulmonary Hypertension. *Journal of Clinical Medicine*, **2021**, 10, | 5.1 | 0 |

| | | | |
|---|---|---|---|
| 31 | Sudden Cardiac Death in Systemic Sclerosis: Diagnostics to Assess Risk and Inform Management. **2021**, 11, | | 0 |
| 30 | The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis. **2019**, 8, | | 3 |
| 29 | New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension. **2019**, 26, 2844-2864 | | 11 |
| 28 | Systemic Sclerosis and Other Connective Tissue Diseases. **2017**, 16, 55-60 | | |
| 27 | Gaps and Controversies of New Treatment Recommendations in Recent Pulmonary Hypertension Guidelines: What We Know and What We Don't. **2017**, 16, 20-25 | | |
| 26 | III. The Particularity of CTD-PH Management. **2018**, 107, 214-218 | | |
| 25 | Pulmonary involvement in systemic lupus erythematosus, Sjögren syndrome and mixed connective tissue disease. **2019**, 106-123 | | 1 |
| 24 | Türkiye'de tersiyer bir merkezde sistemik skleroz hastalarında pulmoner hipertansiyon taraması; kesitsel orjinal çalışma. | | |
| 23 | BOEHRINGER INGELHEIM - Fibroses pulmonaires : maladies pulmonaires ou maladies systémiques ?. **2020**, 12, S58-S63 | | |
| 22 | Beyond Scleroderma: Pulmonary Arterial Hypertension in Patients with Other Connective Tissue Diseases. **2020**, 51-60 | | |
| 21 | Tratamiento farmacológico de la hipertensión pulmonar asociada a la esclerosis sistémica: revisión sistemática de la literatura. **2020**, 27, 135-145 | | |
| 20 | Pulmonary Hypertension Associated with Connective Tissue Disease. *Cardiology Clinics*, **2022**, 40, 29-43 | 2.5 | 1 |
| 19 | 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. *Russian Journal of Cardiology*, **2022**, 26, 4683 | 1.3 | 9 |
| 18 | Upfront Combination Therapy: Growing the Case to Get Ahead of Pediatric Pulmonary Arterial Hypertension.. *Annals of the American Thoracic Society*, **2022**, 19, 163-165 | 4.7 | |
| 17 | Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies.. *Frontiers in Medicine*, **2021**, 8, 788250 | 4.9 | 3 |
| 16 | The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.. *Pharmacology & Therapeutics*, **2022**, 108192 | 13.9 | 1 |
| 15 | Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan. *JACC Asia*, **2022**, 2, 273-284 | | 0 |
| 14 | Effect of vasodilator and immunosuppressive therapy on the endothelial dysfunction in patients with systemic sclerosis. *Clinical and Experimental Medicine*, | 4.9 | 1 |

| | | | |
|---|---|---|---|
| 13 | Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography. *Journal of Clinical Medicine*, **2022**, 11, 4034 | 5.1 | 0 |
| 12 | New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. **2022**, 11, 4631 | | 0 |
| 11 | Pulmonary Hypertension in Scleroderma: Evaluation and Management. **2022**, 101468 | | 0 |
| 10 | VIII. Progress in the Management of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease. **2021**, 110, 2213-2220 | | 0 |
| 9 | Pulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis. **2023**, 19, 45-54 | | 0 |
| 8 | Systemic sclerosis. **2022**, | | 2 |
| 7 | Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. **2023**, 22, 103312 | | 0 |
| 6 | Interstitial Lung Disease. **2023**, 49, 279-293 | | 0 |
| 5 | Pulmonary Hypertension. **2023**, 49, 345-357 | | 0 |
| 4 | State-of-the-art evidence in the treatment of systemic sclerosis. **2023**, 19, 212-226 | | 0 |
| 3 | Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag. | | 0 |
| 2 | Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD). **2023**, 13, | | 0 |
| 1 | Lung Disease in Systemic Lupus Erythematosus, Myositis, Sjögren's Disease, and Mixed Connective Tissue Disease. **2023**, 223-239 | | 0 |